|
InSolution™ Cdk1 Inhibitor IV, RO-3306
5-(Quinolin-6-ylmethylene)-2-(thiophen-2-ylmethylamino)thiazol-4(5H)-one, 5-(6-Quinolinylmethylene)-2-((2-thienylmethyl)amino)-4(5H)-thiazolone
A cell-permeable quinolinyl thiazolinone compound that acts as a potent and ATP-competitive inhibitor of Cdk1 (Ki = 35 nM and 110 nM for Cdk1/B1 and Cdk1/A, respectively). It affects Cdk2/E, PKCδ, and SGK only at much higher concentrations (Ki = 340, 318, and 497 nM, respectively), and shows little effect against Cdk4/D and six other commonly studied kinases (Ki =2 µM). Short-term treatment for up to 20 hrs results in fully reversible G2/M cell cycle arrest, while prolonged treament (>48 hrs) results in apoptotic cell death in proliferating cancer cells, but not in nontumorigenic epithelial cell lines. The solid form of this compound (Cat. No. 217699) is also available.
产品信息
Form Liquid
Formulation A 10 mM (2 mg/569 µL) solution of Cdk1 Inhibitor IV, RO-3306 (Cat. No. 217699) in DMSO.
Primary Target Cdk1/B1 and Cdk1/A
Primary Target Ki 35 nM and 110 nM for Cdk1/B1 and Cdk1/A,
Secondary target Cdk2/E, PKCδ, and SGK
Molar mass 351.5
Protect from Light 是的
Hygrocopic 是的
Avoid freeze/thaw 是的
Packaged under inert gas 是的
Cell permeable 是的
Reversible 是的
Purity ≥95% by HPLC
商店和运输信息
Storage ≤ -70°C
Ship Dry Ice Only
Irritant
安全标示
S Phrase S: 26-36
In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
Wear suitable protective clothing.
R Phrase R: 36/38
Irritating to eyes and skin. |